gip receptor vs glp-1 Schematic illustration of monoagonists, dual agonists and triple GLP-1 and GIP agonism and

This one does something different

4 Clinical evidence In adults with obesity, 72 weeks of orforglipron treatment resulted in greater body-weight reductions than placebo, up to -11.2%, compared to -2.1% with placebo

Since then, hundreds of preclinical studies have reported reduced intake, reward or relapse across a wide range of substances, including alcohol, nicotine, cocaine, amphetamines and opioids

If you experience significant nausea, loss of appetite beyond expectations, mood changes, or signs of dehydration, contact your provider immediatelydose adjustments or timing changes may be needed to optimize both medications

Its stability relies upon the quality of storage area and packaging of formulation